Eylea (Aflibercept), a recombinant fusion protein containing the extracellular domains of VEGF receptors 1 and 2 (VEGFR1 and VEGFR2) fused to the fragment crystallization (Fc) region of human IgG1, is commonly used for the treatment of wet AMD due to its strong binding affinity for VEGF165a4. This evidence concerns the gene FLT1 and wet macular degeneration.